Novartis AG Sponsored ADR(NVS.US)CEO: The market's concerns about Trump's pharmaceutical policies are exaggerated.

Pharmaceutical giant Novartis AG Sponsored ADR, headquartered in Switzerland, CEO Vas Narasimhan said that the industry policy measures of the newly appointed Trump administration may benefit pharmaceutical companies, and the market's concerns about vaccines, broad pharmaceutical policies, and public health funding are "exaggerated". Narasimhan stated in a recent interview that the new health policies of the Trump administration may be helpful to pharmaceutical companies, and the company is focused on reversing some of the actions taken by the previous administration. Narasimhan said in a media interview that Novartis AG Sponsored ADR hopes to work to reverse some policies of the previous US government that have had a chilling effect on innovation. He mentioned the former US President Joe Biden's "Inflation Reduction Act," which allows the government to negotiate prices for certain key drugs. US pharmaceutical giant Eli Lilly and Company, last week, expressed that US pharmaceutical companies will request the new government led by Trump to pause drug price negotiations. "If we can address some elements in US public policy, such as the 'Inflation Reduction Act' and some other aspects, this could actually bring major good news to the industry." Narasimhan said in an interview with the media at the World Economic Forum in Davos. "We believe this year could be a very crucial moment." The "Inflation Reduction Act" allows the US government to significantly reduce the purchase prices for a range of old but popular drugs under the federal Medicare program for the elderly. Even the latest round of federal negotiations has led to a 22% decrease in the average purchase price of pharmaceuticals for the federal government's Medicare insurance. Like other leaders in the pharmaceutical industry, Narasimhan did not choose to criticize the nominated US Secretary of Health Robert F. Kennedy, who is a prominent vaccine critic and COVID vaccine skeptic, and has harshly accused pharmaceutical companies of corruption and "mass poisoning the market." One of the first industry measures taken by Trump after taking office was to issue an executive order announcing the withdrawal of the US from the World Health Organization, cutting off one of the organization's largest sources of funding. "There is a policy environment, as well as rhetoric, and I believe we can actually create a positive industry policy environment." Narasimhan said. Pharmaceutical companies need to "educate the American people and the people around the world that our data is very reliable, and vaccine products are very safe."